Condensed Combined Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 44,679	$ 34,915
Marketable securities	38,594	61,146
Due from related parties	2,057	2,003
Prepaid expenses and other current assets (including amounts with related parties)	14,242	13,649
Total current assets	99,572	111,713
Marketable securities, noncurrent	1,000	950
Property, plant and equipment, net	80,875	72,541
Non-marketable equity investment (Note 4)	0	7,849
Intangible asset, net	1,438	1,463
Convertible note receivable	6,191	6,129
Operating lease right-of-use assets, net (including amounts with related parties)	18,447	18,138
Other assets (including amounts with related parties)	1,905	2,598
Total assets	209,428	221,381
Current liabilities:
Accounts payable	20,097	11,510
Accrued expenses and other liabilities	36,793	36,771
Due to related parties	17,817	14,838
Operating lease liabilities (including amounts with related parties)	5,156	5,015
Total current liabilities	79,863	68,134
Related-party notes payable	297,286	254,353
Operating lease liabilities, less current portion (including amounts with related parties)	16,554	16,179
Deferred income tax liability	170	170
Other liabilities	891	1,035
Total liabilities	394,764	339,871
Commitments and contingencies (Note 8)	0	0
Stockholders’ deficit:
Common stock, $0.0001 par value; 500,000,000 shares authorized; 383,067,321 and 382,243,142 shares issued and outstanding as of March 31, 2021 and December 31, 2020, respectively; excluding treasury stock, 163,800 shares outstanding as of March 31, 2021 and December 31, 2020, respectively	38	38
Additional paid-in capital	1,508,958	1,495,163
Accumulated deficit	(1,694,745)	(1,615,131)
Accumulated other comprehensive (loss) income	(38)	122
Total ImmunityBio stockholders’ deficit	(185,787)	(119,808)
Noncontrolling interests	451	1,318
Total stockholders’ deficit	(185,336)	(118,490)
Total liabilities and stockholders’ deficit	$ 209,428	$ 221,381